Guidelines for the management of Helicobacter pylori infection in Japan: 2024 revised edition
Japanese Society for Helicobacter Resear… · 2026 · Japan
Source and licence
- Authors
- Hajime Isomoto, Tadashi Shimoyama, Masanori Ito et al.
- Title
- Guidelines for the management of Helicobacter pylori infection in Japan: 2024 revised edition
- Journal
- Journal of Gastroenterology, 2026
- Licence
- CC BY 4.0
- Changes
- Verbatim excerpts; formatting adapted
Full text retrieved 2026-10-27 from Europe PMC · PMC13283202
Licence statement of the original publication
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.
Open the original publication →Full text on Europe PMC
Recommendations
Verbatim, with grade of recommendation or strength of consensus where given.
CQ4-1
- We recommend implementing H. pylori infection testing as a public health measure for asymptomatic adolescents aged ≥ 12 years.
CQ4-4
- We recommend SAT or urine antibody tests.
Abstract
Background: The Japanese Society for Helicobacter Research (JSHR) published the fifth edition of the guidelines for the management of Helicobacter pylori (H. pylori) infection in 2024 in Japanese language.
Methods: This edition of JSHR guidelines was first developed in accordance with the Minds Clinical Practice Guideline and Grading of Recommendations Assessment, Development, and Evaluation system. This was published after inviting public comments and external evaluations. Consensus on clinical questions (CQs) was achieved using the modified Delphi method.
Results: There was no change in the basic policy that all H. pylori infectious diseases are indications for eradication. Nucleic acid amplification was added to the diagnostic methods. Effects of proton-pump inhibitors (PPIs) on diagnostic tests were updated. The superiority of potassium-competitive acid blockers to PPIs in 1-week triple therapy with amoxicillin and clarithromycin has been shown. A flowchart for eradication therapy was provided for use in real-world settings. For gastric cancer prevention, eradication in earlier age is recommended. The most appropriate test and treatment strategies for adolescents are also described. Some CQs concerning gastric cancer prevention were identified, although evidence level was insufficient to make recommendations based on clinical importance.
Conclusion: The revised guidelines facilitate the appropriate management of H. pylori infection and gastric cancer prevention.
Contents of the original publication
The section headings of the original.
- Introduction
- Diagnosis
- Selected BQs in diagnosis
- CQ1-1
- CQ1-2
- CQ1-3
- CQ1-4
- Treatment
- Selected BQs in treatment
- CQ2-1
- CQ2-2
- CQ2-3
- CQ2-4
- CQ2-5
- CQ2-6
- CQ2-7
- CQ2-8
- CQ2-9
- CQ2-10
- CQ2-11
- CQ2-12
- CQ2-13
- CQ2-14
- Gastric cancer prevention (adults)
- CQ3-1
- CQ3-2
- CQ3-3
- CQ3-4
- CQ3-5
- CQ3-6
- Gastric cancer prevention (adolescents)
- CQ4-1
- CQ4-2
- CQ4-3
- CQ4-4
- CQ4-5
A question about this guideline?
Medelix answers clinical questions from guidelines and studies – every statement with its source.
Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint